July 24, 2025

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

Symbol: LUPIN

BSE Limited
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

Subject: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

Dear Sir/Madam,

We are pleased to enclose a Press Release as regards, receipt of approval from the U.S. FDA for the Company's Abbreviated New Drug Applications for Liraglutide Injection Single-Patient-Use Prefilled Pens and Glucagon for Injection vials.

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

AMIT KUMAR GUPTA

Digitally signed by AMIT KUMAR GUPTA
DN: c=IN, st=Maharashtra, 2.5.4.20=f72cf02f52d2a7e595b45b846559bdca28c8f26a939bbb35835a169f2a237229a3, postalCode=400705, street=C701 Shivdarshan CHS Ltd Sector16 Plot No5 Navi Mumbai, pseudonym=d3a468d0d03546efabffd2a7cb7aabae, title=7875, serialNumber=8d9bdd80d8994e4be9f0dd2399144eba7e782d70287df6aad1994f0b522fa08a, o=Personal, cn=AMIT KUMAR GUPTA
Date: 2025.07.24 10:48:34 +05'30'

AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)

Encl: a/a.

Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPCIN

Lupin Receives US FDA Approvals for Liraglutide and Glucagon Injectable Products

Mumbai, Naples, July 24, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Applications for Liraglutide Injection Single-Patient-Use Prefilled Pens and Glucagon for Injection vials. Both these products will be manufactured at Lupin's Injectable facility at Nagpur, India.

Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza® Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older, with type 2 diabetes mellitus. Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen (RLD Victoza®) had an estimated annual sale of USD 458 million in the U.S. (IQVIA MAT May 2025).

Glucagon for Injection USP, 1 mg/vial, packaged in an emergency kit[1], is bioequivalent to Glucagon for Injection, 1 mg/vial of Eli Lilly and Company. It is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. Glucagon for Injection USP, 1 mg/vial, had an estimated annual sale of USD 124 million in the U.S. (IQVIA MAT May 2025).

Dr. Shahin Fesharaki, Chief Scientific Officer, Lupin said, "We are pleased to obtain the USFDA approvals for two of our complex injectable products. This is a meaningful enhancement to our portfolio and reaffirms our commitment to expanding access to critical therapies for our patients."

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries please contact –
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

rajalakshmiazariah@lupin.com

Safe Harbor Statement

Victoza® is a registered trademark of Novo Nordisk A/S.

[1] We note that the RLD upon which you have based this ANDA, Eli Lilly's Glucagon for Injection, 1 mg/vial, is no longer being marketed in the United States and is currently listed in the discontinued section of FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book"). The Agency has determined that Eli Lilly's Glucagon for Injection, 1 mg/vial, was not withdrawn from sale for reasons of safety or effectiveness. FDA published this determination in the Federal Register (89 FR 64928; August 8, 2024). This determination allows the Agency to approve ANDAs for the discontinued drug product.